Home » Waters Acquires Thermometric for $2.5 M
Waters Acquires Thermometric for $2.5 M
PharmaManufacturing.com
09/04/2006
Waters Corp. (Milford, Mass.) on Aug. 28 announced the acquisition of all the outstanding capital stock of privately held Thermometric AB (Jarfalla, Sweden), a manufacturer of high-performance microcalorimeters, for approximately $2.5 million. Waters plans to merge the acquired business into its TA Instruments Inc. (New Castle, Del.) operation. Thermometric has annual sales of approximately $4 million and this transaction is expected to be neutral to Waters 2006 earnings.
Commenting on the acquisition, Terry Kelly, President of TA Instruments said, "The technologies and products from Thermometric are complementary to our leading position in thermal analysis and will allow us to expand our business into new applications, especially in life science research."
Waters Corp. holds worldwide leading positions in three complementary analytical technologies: liquid chromatography, mass spectrometry and thermal analysis. These markets account for approximately $5 billion of the overall $20 - $25 billion analytical instrument market.
For more information on Waters, visit www.waters.com
Thermometric AB operated as a privately held company in Jarfalla, Sweden. Their flagship product, the TAM III, is a modular calorimeter that employs proprietary technology to deliver unparalleled calorimetric sensitivity and temperature stability. It is routinely used to characterize materials, and their interactions, in the fields of pharmaceuticals, life and materials sciences.
To learn more about Thermometric AB, visit www.thermometric.com.
More News:
- 03/18/2010 Teva Beats Out Pfizer & Activa in 3.5BN Rationpharm Generics DealFrom CTV.ca
- 03/18/2010 Johnson & Johnson CEO Weldon Gets 11% 2009 Raise, to $25.6MFrom AP.com
- 03/17/2010 $75 Million Drug Heist is Bitter Pill for LillyFrom IndyStar.com
- 03/17/2010 R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
- 03/15/2010 Diabetes Drug From Lilly, Amylin Under ScrutinyFrom Forbes.com
- 03/12/2010 AstraZeneca Inks First Generic Drugs DealFrom Business.timesonline.co.uk
- 03/12/2010 AstraZeneca Job Cuts Reflect New Landscape For Drug InnovationFrom FT.com
- 03/10/2010 Novartis Goes Wireless for Process and Plant Info
- 03/10/2010 Concerns Raised about Tromethamine ContaminationFrom Rx-360
- 03/09/2010 Pittcon 2010: Thermo Fisher Scientific Continues in Growth Mode
- All news »
Get Connected Now!
- Featured White Papers

Print page